Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Weishuning Tablets (胃舒宁片) is a Traditional Chinese Medicine (TCM) product developed and marketed by Shaanxi Kanghui Pharmaceutical. Formulated as an oral tablet, it is part of the company's approved and commercialized portfolio of Chinese patent medicines. The drug is primarily indicated for gastrointestinal conditions, particularly those characterized by stomach pain, hyperacidity, and symptoms associated with chronic gastritis. In the context of Traditional Chinese Medicine theory, it is typically used to soothe the liver, regulate Qi, and harmonize the stomach. While specific herbal constituents for the Shaanxi Kanghui formulation are not detailed in the provided text, standard Weishuning formulations often include ingredients such as Corydalis rhizome, Glycyrrhiza, and Sepiae Endoconcha to provide analgesic and antacid effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Weishuning Tablets.